In a report released yesterday, Michael Okunewitch from Maxim Group maintained a Buy rating on Longeveron (LGVN – Research Report), with a price target of $14.00. The company’s shares opened today at $2.85.
Okunewitch covers the Healthcare sector, focusing on stocks such as Kiora Pharmaceuticals, Citius Pharmaceuticals, and BioRestorative Therapies. According to TipRanks, Okunewitch has an average return of -18.3% and a 31.91% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Longeveron with a $13.25 average price target.
See Insiders’ Hot Stocks on TipRanks >>
LGVN market cap is currently $58.53M and has a P/E ratio of -3.17.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Longeveron LLC is a biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. It is involved in sponsoring clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS).
Read More on LGVN:
- Longeveron announces first patient dosed in Phase 2 trial of lomecel-B
- Longeveron CFO resigns from position
- Longeveron reports Q4 EPS (21c) vs (20c) last year
- Longeveron Inc. Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
- Longeveron to Announce Fourth Quarter and Full Year Financial Results on March 10, 2023
